Eversept Partners, LP
- SEC CIK
- 0001697013
- Latest filing
- Aug 14, 2026
UTHR holding history
United Therapeutics Corp in every 13F filed by Eversept Partners, LP, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
UTHR overviewAll 13F holders of UTHRFull Q2 2026 holdings
- Shares (Q2 2026)
- 287,668
- Value
- $155.9M
- % of portfolio
- 8.5%
- Quarters held
- 22
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 287,668 | $155.9M | 8.5% | +23,397+8.9% | Added | Holders |
| Q1 2026 | 264,271 | $156.7M | 10.3% | +11,679+4.6% | Added | Holders |
| Q4 2025 | 252,592 | $123.1M | 6.9% | −628−0.2% | Reduced | Holders |
| Q3 2025 | 253,220 | $106.2M | 8.1% | +193,854+326.5% | Added | Holders |
| Q2 2025 | 59,366 | $17.1M | 1.7% | +1,877+3.3% | Added | Holders |
| Q1 2025 | 57,489 | $17.7M | 2.0% | +13,786+31.5% | Added | Holders |
| Q4 2024 | 43,703 | $15.4M | 1.6% | −87,246−66.6% | Reduced | Holders |
| Q3 2024 | 130,949 | $46.9M | 3.6% | −104,402−44.4% | Reduced | Holders |
| Q2 2024 | 235,351 | $75.0M | 5.7% | −15,784−6.3% | Reduced | Holders |
| Q1 2024 | 251,135 | $57.7M | 4.3% | +4,901+2.0% | Added | Holders |
| Q4 2023 | 246,234 | $54.1M | 5.3% | −21,669−8.1% | Reduced | Holders |
| Q3 2023 | 267,903 | $60.5M | 6.7% | +7,505+2.9% | Added | Holders |
| Q2 2023 | 260,398 | $57.5M | 6.1% | +38,291+17.2% | Added | Holders |
| Q1 2023 | 222,107 | $49.7M | 4.5% | −10,680−4.6% | Reduced | Holders |
| Q4 2022 | 232,787 | $64.7M | 6.2% | −22,439−8.8% | Reduced | Holders |
| Q3 2022 | 255,226 | $53.4M | 6.3% | −55,608−17.9% | Reduced | Holders |
| Q2 2022 | 310,834 | $73.2M | 7.2% | +18,600+6.4% | Added | Holders |
| Q1 2022 | 292,234 | $52.4M | 4.8% | −99,686−25.4% | Reduced | Holders |
| Q4 2021 | 391,920 | $84.7M | 7.0% | −52,551−11.8% | Reduced | Holders |
| Q3 2021 | 444,471 | $82.0M | 6.6% | +1,526+0.3% | Added | Holders |
| Q2 2021 | 442,945 | $79.5M | 7.4% | −43,584−9.0% | Reduced | Holders |
| Q1 2021 | 486,529 | $81.4M | 6.7% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.